|
| 37230980 | Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. | | 2023 |
| 35658469 | Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. | Journal of Clinical Oncology | 2023 |
| 37741459 | Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial. | | 2023 |
| 36951061 | Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease. | | 2023 |
| 36878906 | Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. | | 2023 |
| 36745126 | Impact of integrated translational research on clinical exome sequencing. | Genet Med | 2023 |
| 36546453 | Adjusted comparison of outcomes between patients from CARTITUDE-1 multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world cl | | 2023 |
| 35211412 | Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. | Front Oncol | 2022 |
| 35709201 | Metagenomic shotgun sequencing of blood to identify bacteria and viruses in leukemic febrile neutropenia. | PLoS One | 2022 |
| 35653112 | Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. | Blood Cancer Discov | 2022 |
| 35646666 | Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. | Front Oncol | 2022 |
| 36215989 | Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. | Lancet Haematology,The | 2022 |
| 36051067 | Transcriptional profiles define drug refractory disease in myeloma. | | 2022 |
| 33857637 | Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. | Clin Gastroenterol Hepatol | 2022 |
| 34782326 | Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. | Cancer Prev Res (Phila) | 2022 |
| 34620795 | Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. | Clin Transl Gastroenterol | 2021 |
| 33971243 | Protein expression and purification of G-protein coupled receptor kinase 6 (GRK6), toward structure-based drug design and discovery for multiple myeloma. | Protein Expr Purif | 2021 |
| 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet, The | 2021 |
| 33580975 | Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. | American Journal of Hematology | 2021 |
| 33890576 | Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting. | Mayo Clin Proc | 2021 |
| 33144682 | Impact of integrated translational research on clinical exome sequencing. | Genet Med | 2021 |
| 33126242 | Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. | JAMA Oncol | 2021 |
| 32842143 | Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma. | Blood | 2021 |
| 32561655 | Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity. | Molecular Cancer Research | 2020 |
| 31582538 | Identification of PIKfyve kinase as a target in multiple myeloma. | Haematologica | 2020 |
| 32108443 | Once-weekly (70 mg/m ) vs twice-weekly (56 mg/m ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. | Cancer Medicine | 2020 |
| 32393731 | Direct to Drug screening as a precision medicine tool in multiple myeloma. | Blood Cancer Journal | 2020 |
| 31558666 | IKZF1/3 and CRL4 E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. | Haematologica | 2020 |
| 33203829 | Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. | Blood Cancer J | 2020 |
| 31320253 | Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: AÂ Case of Unrecognized t(2;11) Structural Variation. | Clinical Lymphoma, Myeloma and Leukemia | 2019 |
| 31844041 | Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. | Blood Cancer J | 2019 |
| 30026573 | Spectrum and functional validation of PSMB5 mutations in multiple myeloma. | Leukemia | 2019 |
| 29967379 | A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. | Leukemia | 2019 |
| 29988062 | Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. | Bone Marrow Transplantation | 2019 |
| 29690814 | Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report. | Journal of Oncology Pharmacy Practice | 2019 |
| 31177537 | Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. | Br J Haematol | 2019 |
| 30741931 | Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. | Blood Cancer J | 2019 |
| 31433920 | Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. | N Engl J Med | 2019 |
| 31256854 | Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. | Mayo Clin Proc | 2019 |
| 30718503 | Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. | Blood Cancer Journal | 2019 |
| 29797255 | Protocol for MP: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma. | Methods in Molecular Biology | 2018 |
| 28860655 | Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. | Leukemia | 2018 |
| 29980678 | Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. | Blood Cancer Journal | 2018 |
| 29884741 | Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. | Blood | 2018 |
| 30305608 | Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. | Blood Cancer J | 2018 |
| 30061664 | Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. | Blood Cancer J | 2018 |
| 29866475 | Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. | Lancet Oncology, The | 2018 |
| 29954938 | Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. | Haematologica | 2018 |
| 29991494 | Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. | Blood advances | 2018 |
| 29623394 | Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. | Annals of Hematology | 2018 |